Steatosis and NASH in type 2 diabetes

被引：44
|
作者：
Hu, Mengyue [1 ,2 ]
Phan, Franck [1 ,2 ]
Bourron, Olivier [1 ,2 ,3 ,4 ]
Ferre, Pascal [1 ,2 ]
Foufelle, Fabienne [1 ,2 ,3 ,4 ]
机构：
[1] Sorbonne Univ, INSERM UMRS 1138, Ctr Rech Cordeliers, F-75006 Paris, France
[2] Univ Paris Diderot, Ctr Rech Cordeliers, Sorbonne Paris Cite, Univ Paris Descartes, F-75006 Paris, France
[3] AP HP, Dept Endocrinol Nutr & Diabet, Paris, France
[4] Hop La Pitie Salpetriere, AP HP, ICAN, Paris, France
来源：
BIOCHIMIE | 2017年 / 143卷
关键词：
Steatosis; NASH; Insulin resistance; Inflammation; Lipotoxicity; Type; 2; diabetes; FATTY LIVER-DISEASE; DE-NOVO LIPOGENESIS; NF-KAPPA-B; INSULIN-RESISTANCE; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; IKK-BETA; RISK; OBESITY; MICE;
D O I：
10.1016/j.biochi.2017.10.019
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Non Alcoholic Fatty Liver Disease (NAFLD) is currently the most common chronic liver disease in the world, encompassing various conditions ranging from simple steatosis, steatohepatitis, to fibrosis and cirrhosis. The association between NAFLD and Type 2 Diabetes (T2D) is strong and complex, given that the prevalence of NAFLD is particularly high in individuals with Type 2 Diabetes. In fact, insulin resistance occurring in this metabolic disease can promote NAFLD development, and vice versa, NAFLD can enhance insulin resistance. In this review, we focus on the mechanisms linking NAFLD and T2D, including fatty acid accumulation, inflammation, oxidative stress etc. We also discuss about situations showing a dissociation between steatosis and insulin resistance, in order to provide new insights for NAFLD therapeutic targets. (C) 2017 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
引用
收藏
页码：37 / 41
页数：5
相关论文
共 50 条
  • [1] HEPATIC STEATOSIS AS DIABETES TYPE 2 PREDICTOR
    Loureiro, Carolina
    Martinez-Aguayo, Alejandro
    Campino, Carmen
    Carvajal, Cristian
    Fardella, Carlos
    Garcia, Hernan
    NUTRICION HOSPITALARIA, 2014, 29 (02) : 350 - 358
  • [2] Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations
    Apostolov, Ross
    Gianatti, Emily
    Wong, Darren
    Kutaiba, Numan
    Gow, Paul
    Grossmann, Mathis
    Sinclair, Marie
    WORLD JOURNAL OF HEPATOLOGY, 2022, 14 (04) : 754 - U128
  • [3] Treatment with a Catalytic Superoxide Dismutase (SOD) Mimetic Improves Liver Steatosis, Insulin Sensitivity, and Inflammation in Obesity-Induced Type 2 Diabetes
    Coudriet, Gina M.
    Delmastro-Greenwood, Meghan M.
    Previte, Dana M.
    Marre, Meghan L.
    O'Connor, Erin C.
    Novak, Elizabeth A.
    Vincent, Garret
    Mollen, Kevin P.
    Lee, Sojin
    Dong, H. Henry
    Piganelli, Jon D.
    ANTIOXIDANTS, 2017, 6 (04)
  • [4] High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus
    Gupta, Aanchal
    Anoop, Shajith
    Ansari, Irshad Ahmad
    Prakash, Satya
    Misra, Anoop
    CLINICAL NUTRITION ESPEN, 2021, 46 : 519 - 526
  • [5] The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes
    Hashimoto, Yoshitaka
    Osaka, Takafumi
    Fukuda, Takuya
    Tanaka, Muhei
    Yamazaki, Masahiro
    Fukui, Michiaki
    ENDOCRINE JOURNAL, 2016, 63 (10) : 877 - 884
  • [6] Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes
    Leon-Mimila, P.
    Villamil-Ramirez, H.
    Li, X. S.
    Shih, D. M.
    Hui, S. T.
    Ocampo-Medina, E.
    Lopez-Contreras, B.
    Moran-Ramos, S.
    Olivares-Arevalo, M.
    Grandini-Rosales, P.
    Macias-Kauffer, L.
    Gonzalez-Gonzalez, I
    Hernandez-Pando, R.
    Gomez-Perez, F.
    Campos-Perez, F.
    Aguilar-Salinas, C.
    Larrieta-Carrasco, E.
    Villarreal-Molina, T.
    Wang, Z.
    Lusis, A. J.
    Hazen, S. L.
    Huertas-Vazquez, A.
    Canizales-Quinteros, S.
    DIABETES & METABOLISM, 2021, 47 (02)
  • [7] Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
    Kim, Hyunmi
    Lee, Da Som
    An, Tae Hyeon
    Park, Hyun-Ju
    Kim, Won Kon
    Bae, Kwang-Hee
    Oh, Kyoung-Jin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [8] Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD
    Reeves, Helen L.
    Zaki, Marco Y. W.
    Day, Christopher P.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1234 - 1245
  • [9] Bcl10 and methylation of fatty acids: a future therapeutic target for Type 2 diabetes?
    Jornayvaz, Francois R.
    CLINICAL LIPIDOLOGY, 2012, 7 (05) : 493 - 495
  • [10] Association between liver steatosis, fibrosis, and the onset of type 2 diabetes in overweight individuals: A fibroscan-based study in Southern Italy
    Guido, Davide
    Cerabino, Nicole
    Di Chito, Martina
    Di Stasi, Vincenza
    De Nucci, Sara
    Shahini, Endrit
    Giannuzzi, Vito
    Cozzolongo, Raffaele
    Coletta, Sergio
    Stabile, Dolores
    Ancona, Anna
    Longo, Giovanna
    Fontana, Luigi
    Giannelli, Gianluigi
    De Pergola, Giovanni
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 218
12345